• Doxorubicin (Adriamycin) HCl: Lab Scenarios

  2026-08-22

  This scenario-driven guide explains how Doxorubicin hydrochloride, also known as Adriamycin HCl, can improve experimental planning for viability, proliferation, apoptosis, and cardiotoxicity studies. It provides practical guidance for selecting concentrations, controlling solvent and storage variables, interpreting assay endpoints, and evaluating SKU A1832 for routine laboratory use.

• SU5416 (Semaxanib) VEGFR2 Research Workflows

  2026-08-22

  SU5416 (Semaxanib) supports controlled studies of VEGFR2 signaling, endothelial angiogenesis, tumor vascularization, and SU5416-induced pulmonary hypertension models. Its value is highest when target engagement, cardiopulmonary performance, skeletal-muscle assays, and AHR-linked immune readouts are interpreted as separate but connected experimental layers.

• EdU Imaging Kits (Cy3) for Fibroblast S-Phase Assays

  2026-08-21

  Apply EdU Imaging Kits (Cy3) to separate true fibroblast DNA synthesis from activation, migration, or survival changes in polystyrene nanoplastic models. The denaturation-free click-chemistry workflow supports both quantitative imaging and flow cytometry while preserving morphology and compatibility with protein co-staining.

• Epinephrine Bitartrate: Adrenergic Research Guide

  2026-08-20

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for controlled studies of α- and β-adrenergic signaling. Its reported receptor activity, concentration range, solubility, and storage requirements support cardiovascular disease research, sympathetic nervous system research, and cell-based assay development when experimental and clinical boundaries are kept explicit.

• PMSF for Protein Extraction and eIF3 Workflows

  2026-08-20

  PMSF protects serine-sensitive proteins during cold extraction, Western blot sample preparation, and purification of fragile multiprotein assemblies. This guide connects practical PMSF handling with the recombinant eIF3 purification strategy reported in a recent reference study, while emphasizing selectivity, timing, and troubleshooting.

• Epidermal Growth Factor: From Binding to Translation

  2026-08-19

  Epidermal Growth Factor is more than a cell-growth supplement: it is a controllable perturbation for dissecting receptor signaling, migration, invasion, and mucosal biology. This thought-leadership guide connects recombinant human EGF quality attributes with experimental strategy and translational decision-making.

• NPC1/USP7/p53 Axis in HCC Cholesterol Control

  2026-08-19

  The reference study identifies NPC1 as a multifaceted regulator of hepatocellular carcinoma progression, linking lysosomal cholesterol handling to USP7-dependent destabilization of p53 and SREBP2-associated lipid regulation. Its perturbation-and-rescue design suggests that proliferation, p53 activity, and cholesterol distribution should be evaluated together rather than as isolated phenotypes.

• Exo1 and the Translational Logic of Exocytic Control

  2026-08-18

  Exo1 offers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership perspective explains how translational researchers can use Exo1 as a causal perturbation tool when evaluating tumor extracellular vesicle biology, while maintaining a clear boundary between preclinical assay evidence and therapeutic claims.

• Bifendate (DDB) Workflows for Liver Research

  2026-08-18

  Build reproducible liver-cell, lipid-accumulation, autophagy, and drug-interaction assays with Bifendate (DDB). This practical guide connects formulation control and pathway-resolved readouts with CYP3A4 and P-glycoprotein safety workflows.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-08-17

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular signal that promotes M2 macrophage polarization through JAK2/STAT6 pathway engagement. Its findings connect a noncoding RNA cargo with an immunosuppressive tumor-microenvironment phenotype and provide a framework for testing pathway dependence in hepatocellular carcinoma models.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-17

  A 2025 study found that naturally occurring angiotensin peptide fragments can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, or NRP1 in receptor-specific patterns. The work identifies peptide length and tyrosine modification as important variables, while also showing why these findings require validation beyond antibody-based binding assays.

• PD 173074: Structure and Angiogenesis Inhibition

  2026-08-16

  The reference study established a structural explanation for how PD 173074 inhibits FGFR1 and suppresses FGF- and VEGF-driven angiogenesis. By combining kinase assays, mouse experiments, and 2.5 Å X-ray crystallography, it connected ATP-pocket binding with inhibitor selectivity and provided a framework for interpreting FGFR-directed antiangiogenic research.

• Bifendate (DDB): Dose, Lipids, and Assay Design

  2026-08-15

  Bifendate (DDB) is a hepatoprotection agent whose effects depend strongly on dose, timing, tissue, and assay context. This evidence-led guide reconciles its hepatoprotective applications with high-dose triglyceride elevations and translates those findings into better experimental design.

• Biotin Azide as a Molecular Audit Trail for Fzd5

  2026-08-14

  Biotin Azide enables selective click labeling of alkynylated biomolecules, creating a practical molecular audit trail for studying Fzd5–cholesterol–Wnt signaling. This guide connects reagent chemistry with assay design, controls, enrichment, and interpretation without overstating what the chemistry can prove.

• Protease Inhibitor Cocktail for TP53 Assays

  2026-08-14

  Learn how a Protease Inhibitor Cocktail protects TP53-centered protein assays in DHODH inhibitor studies. This guide connects cancer-metabolism findings with practical choices for Western blotting, co-immunoprecipitation, and EDTA-sensitive workflows.

7949 records 1/530 page Next 12345 下5页 Last page